US 11,697,667 B2
Salts and polymorphs of cethromycin for the treatment of disease
David Sullivan, Baltimore, MD (US); Amanda Hill, Cambridge (GB); Kate Wittering, Cambridge (GB); Amy Tapper, Boston, MA (US); and Nikola Kaludov, Deale, MD (US)
Assigned to AliquantumRx, Inc., Baltimore, MD (US)
Filed by AliquantumRx, Inc., Baltimore, MD (US)
Filed on Dec. 2, 2020, as Appl. No. 17/109,970.
Claims priority of provisional application 62/942,508, filed on Dec. 2, 2019.
Prior Publication US 2021/0163522 A1, Jun. 3, 2021
Int. Cl. C07H 17/08 (2006.01); A61P 33/06 (2006.01); A61K 31/706 (2006.01)
CPC C07H 17/08 (2013.01) [A61K 31/706 (2013.01); A61P 33/06 (2018.01); C07B 2200/13 (2013.01)] 21 Claims
OG exemplary drawing
 
1. A compound of structural Formula I

OG Complex Work Unit Chemistry
wherein:
a is a fractional or whole number between about 0.5 and 3.5, inclusive;
b is a fractional or whole number between about 0 and 10, inclusive; and
M is hydrochloric acid,
wherein the compound is characterized by the presence of four or more XRPD peaks with d-spacings chosen from about 14.1, about 12.9, about 10.1, about 8.8, about 8.5, about 6.5, about 5.5, about 5.1, about 4.8, and about 4.4 Å.